New Threads Only:  Add to Google Reader or Homepage
New Threads & Replies:  Add to Google Reader or Homepage
Forums are for serious investors only. GuruFocus Forum Rules.

Forum List » Business News and Headlines
SEC Filings, Earing Reports, Press Releases
New Topic Search
Goto Thread: PreviousNext
Goto: Forum ListMessage ListNew TopicSearchLog In
Maxygen Fourth Quarter and Year End 2008 Financial Results Conference Call Notice
Posted by: gurufocus (IP Logged)
Date: January 27, 2009 06:02AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, will host a conference call to discuss the company’s fourth Press Release: Maxygen Fourth Quarter and Year End 2008 Financial Results Conference Call Notice

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, will host a conference call to discuss the company’s fourth quarter and year end 2008 financial results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, February 10, 2009. Russell Howard, Maxygen’s chief executive officer, will host the call. A press release announcing Maxygen’s fourth quarter and year end 2008 financial results will be issued that same day at approximately 4:00 p.m. ET (1:00 p.m. PT).

Participants in the U.S. can access the call by dialing 866.221.6685 and using the passcode 93293610. International participants can dial 617.896.9885 and use the same passcode. A live webcast of the conference call will be available on the Maxygen web site at www.maxygen.com/webcasts.

Telephone and webcast replays of the conference call will be available until March 10, 2009. To access the telephone replay, dial 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 40855606. To access the webcast archive, go to www.maxygen.com/webcasts.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company’s portfolio includes MAXY-G34, designed to be an improved long-acting G-CSF for the treatment of neutropenia. Maxygen also has a MAXY-4 program, partnered with Astellas Pharma, Inc., under which the company and Astellas are exploring new CTLA4-Ig product candidates for the treatment of a broad array of autoimmune disorders and transplantation rejection. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. www.maxygen.com

Source: BusinessWire


Stocks Discussed: MAXY,
Rate this post:




Sorry, only registered users may post in this forum.

Please Login if you have an account or Create a Free Account if you don't




Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial